Our findings suggest that DG treatment protects against MGN through its antioxidative and anti-inflammatory properties, attributable to Nrf2/Keap1 pathway activation and NF-κB pathway downregulation. Here, NFE2L2 is linked to idiopathic membranous glomerulonephritis.